The Decade of the Brain-the 1990s-was a time of gains in our knowledge of the molecular and genetic basis of Alzheimer's disease (AD). [1] [2] [3] [4] The momentum of discovery and depth of molecular information that developed during that time clearly leads one to predict that it is the end of the beginning of deciphering the pathogenesis of AD leading to effective therapy. Most cases of AD are sporadic; however, the molecular and genetic information of specific genes and other risk factors that cause the familial form of AD will shed light on the etiology of the much more abundant sporadic forms. About 10% of familial disease presents as an autosomal dominant mode of transmission. Epidemiologic studies indicate that about 30% of AD patients have a family history of disease in which at least one first-degree relative is affected. It is clear that early onset autosomal dominant AD is a heterogeneous set of disorders caused in separate families by different genetic mutations. Late-onset sporadic disease is the result of yet-to-bediscovered multiple environmental and genetic influences. In support of this view, only one-third of identical twins are concordant for AD, indicating that nongenetic-perhaps environmental-factors are important in the pathogenesis of AD. Mutations in the amyloid precursor protein gene (APP) on chromosome 21q, and the presenilin 1 and 2 genes (PS1, PS2) on chromosomes 14q and 1q, account for approximately one half of early-onset forms of autosomal dominant inherited disease. An additional locus on chromosome 12 has also been described. It is estimated that 50% of dominantly inherited disease remains yet to be mapped and genetically identified. Although the specific functions of the proteins coded by the APP and the PS1 and PS2 genes are only incompletely known, they share a common effect of abnormally processing APP, resulting in a 50% increase in A␤ 40 or A␤ 42 peptides, which subsequently aggregate to form the neuritic plaque in the AD patient's brain. [1] [2] [3] [4] The increased A␤ synthesis and aggregation constitute a toxic gain-of-function (gain of aggregation) that is characteristic of autosomal dominant genetic disease. These points form the genetic basis for the amyloid hypothesis. The amyloid hypothesis has achieved more than a critical mass of scientific data so it is now appropriately a central construct of AD pathogenesis. An increased synthesis of A␤ from APP in the early-onset forms of AD due to APP and PS1 and PS2 mutations is a central point in support of the amyloid hypothesis, which states that abnormal amyloidogenesis or amyloid clearance are primarily causal of the pathogenesis of AD. Other molecular pathologies are of secondary importance. A more cautious view would be to say that amyloid deposition is necessary but not sufficient to cause the dementia of AD. Other factors also play a role. Additional support for the amyloid hypothesis include: AD brains contain increased numbers of A␤ plaques over time; A␤ deposition precedes clinical symptoms of AD; sporadic AD patients have decreased clearance of A␤ through the CSF; sporadic patients have increased aggregation or decreased turnover of A␤; other systemic amyloidoses are treated by decreasing the concentration of the amyloidogenic protein; A␤ is increased in plasma of persons older than 65 years who later develop AD compared to age-matched controls; Down syndrome patients develop AD due to an extra copy of the APP gene on chromosome 21. Importantly, neuritic amyloid-containing plaques are not innocent: fibrillar A␤ is neurotoxic in vitro and in vivo. Central to the hypothesis, increased accumulation of amyloidogenic peptides A␤ 42 and A␤ 40 occurs as an early event in the disease. This is due to either increased activity of the proteases ␤-and ␥-secretase or de-
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The Decade of the Brain-the 1990s-was a time of gains in our knowledge of the molecular and genetic basis of Alzheimer's disease (AD). [1] [2] [3] [4] The momentum of discovery and depth of molecular information that developed during that time clearly leads one to predict that it is the end of the beginning of deciphering the pathogenesis of AD leading to effective therapy. Most cases of AD are sporadic; however, the molecular and genetic information of specific genes and other risk factors that cause the familial form of AD will shed light on the etiology of the much more abundant sporadic forms. About 10% of familial disease presents as an autosomal dominant mode of transmission. Epidemiologic studies indicate that about 30% of AD patients have a family history of disease in which at least one first-degree relative is affected. It is clear that early onset autosomal dominant AD is a heterogeneous set of disorders caused in separate families by different genetic mutations. Late-onset sporadic disease is the result of yet-to-bediscovered multiple environmental and genetic influences. In support of this view, only one-third of identical twins are concordant for AD, indicating that nongenetic-perhaps environmental-factors are important in the pathogenesis of AD. Mutations in the amyloid precursor protein gene (APP) on chromosome 21q, and the presenilin 1 and 2 genes (PS1, PS2) on chromosomes 14q and 1q, account for approximately one half of early-onset forms of autosomal dominant inherited disease. An additional locus on chromosome 12 has also been described. It is estimated that 50% of dominantly inherited disease remains yet to be mapped and genetically identified. Although the specific functions of the proteins coded by the APP and the PS1 and PS2 genes are only incompletely known, they share a common effect of abnormally processing APP, resulting in a 50% increase in A␤ 40 or A␤ 42 peptides, which subsequently aggregate to form the neuritic plaque in the AD patient's brain. [1] [2] [3] [4] The increased A␤ synthesis and aggregation constitute a toxic gain-of-function (gain of aggregation) that is characteristic of autosomal dominant genetic disease. These points form the genetic basis for the amyloid hypothesis.
Amyloid hypothesis. The primary role of altered amyloidogenesis in the causation of AD has been supported convincingly by data of Selkoe, [5] [6] [7] [8] [9] [10] [11] [12] [13] Glenner and Wong, 14 Goldgaber et al., 15 Tanzi et al., 16 Masters et al., 17 Kowal et al., 18 and Geula et al., 19 among others. The amyloid hypothesis has achieved more than a critical mass of scientific data so it is now appropriately a central construct of AD pathogenesis. An increased synthesis of A␤ from APP in the early-onset forms of AD due to APP and PS1 and PS2 mutations is a central point in support of the amyloid hypothesis, which states that abnormal amyloidogenesis or amyloid clearance are primarily causal of the pathogenesis of AD. Other molecular pathologies are of secondary importance. A more cautious view would be to say that amyloid deposition is necessary but not sufficient to cause the dementia of AD. Other factors also play a role. Additional support for the amyloid hypothesis include: AD brains contain increased numbers of A␤ plaques over time; A␤ deposition precedes clinical symptoms of AD; sporadic AD patients have decreased clearance of A␤ through the CSF; sporadic patients have increased aggregation or decreased turnover of A␤; other systemic amyloidoses are treated by decreasing the concentration of the amyloidogenic protein; A␤ is increased in plasma of persons older than 65 years who later develop AD compared to age-matched controls; Down syndrome patients develop AD due to an extra copy of the APP gene on chromosome 21. Importantly, neuritic amyloid-containing plaques are not innocent: fibrillar A␤ is neurotoxic in vitro and in vivo. Central to the hypothesis, increased accumulation of amyloidogenic peptides A␤ 42 and A␤ 40 occurs as an early event in the disease. This is due to either increased activity of the proteases ␤-and ␥-secretase or de-creased turnover of A␤ peptides, which then aggregate to first form the diffuse and then the mature neuritic plaque. The protease ␣-secretase-which would cut the APP within the A␤ region, rendering it nonamyloidogenic-becomes relatively less important. Polymerized amyloid in the neuritic plaque is in a betapleated sheet configuration, contributing to neurotoxicity. It is of interest that plaque amyloid co-localizes with several key molecules involved in AD pathogenesis, including ubiquitin, APOE, ␣ 1 anti-chymotrypsin, ␣ 2 macroglobulin, and PS1 and PS2.
A fraction of A␤ peptides is produced by recycling endosomes after internalization of APP molecules from the cell surface. Cell surface-labeled APP, allowed to internalize in living cells in culture, results within 15 to 30 minutes in labeled A␤ that could only have been produced from surface-labeled molecules. 5 Most of the A␤ synthesized is A␤ 40 and is detectable in Golgi fractions, whereas A␤ 42 is present in endoplasmic reticulum fractions, as found by Selkoe.
5 Soluble A␤ 40 is the predominant A␤ peptide in human CSF and plasma. In contrast, A␤ 42 , with its extra two hydrophobic residues, isoleucine and alanine, is the A␤ peptide that forms early diffuse plaques and subsequent neuritic plaques.
5 A␤ 42 has the physical property, due to the two additional residues, to aggregate into amyloid fibrils more rapidly and completely than A␤ 40 . 5 Information about A␤ proteolytic degradation is minimal but the protease insulindegrading enzyme is one possible candidate. 5 The APP and presenilin gene mutations activate ␤-and ␥-secretases to increase A␤ synthesis and it is presumed that environmental or other nongenetic factors will also activate them in sporadic AD. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] It has been demonstrated that PC12 neural cells in culture expressing amyloidogenic peptide synthesis can be differentiated further with a pharmacologic agent-phorbol esters-which increases nonamyloidogenic peptide synthesis, perhaps by inducing ␣-secretase in vitro. 20 However, altered turnover or removal of A␤ may also be an important event. Similar biochemical events, it is presumed, are occurring in normal and in sporadic AD brains.
Amyloid precursor protein gene. The APP gene, which maps to chromosome 21q21.2, is causal of some early-onset inherited AD due to several missense mutations in different families, as reported initially in a series of landmark papers beginning in 1987 by St. George-Hyslop et al., 21 Tanzi et al., 22 Van Broeckhoven et al., 23 Goate et al., 24 and Mullan et al. 25 Families with hereditary cerebral hemorrhage with amyloidoses of the Dutch type (HCHWA-D) were reported in 1990 and 1991 in several families in the Netherlands. 26, 27 HCHWA-D results in deposition of A␤ in cerebral blood vessels and also results in recurrent cerebral hemorrhages. A␤ plaques in these patients similar to those found in typical AD patients were also described. The HCHWA-D mutation was identified in codon 693 in exon 16 of the APP gene resulting in a glutamate to glutamine substitution. 26, 28 This mutation is near the proteolytic cleavage site inside the A␤ region. This mutation may result in a decrease of A␤ degradation, resulting in its being accumulated in cerebral blood vessel walls. APP mutations in codon 717 resulting in the substitution of valine by isoleucine, glycine, or phenylalanine, first described by Goate et al., 24 are causal of early-onset autosomal dominant AD. An isoleucine substitution for valine in codon 716 has also been described with dominantly inherited AD. A mutation was found by Hendriks et al. 29 at codon 692 in exon 17 in a family that had both AD type amyloid plaques and cerebral hemorrhages. Mullan et al. 25 described a double tandem mutation in exon 16 involving codons 670/671 in a family with early-onset disease. At least 7 different APP mutations in over 20 families with early-onset dominantly inherited AD have been described to date. [1] [2] [3] [4] All missense mutations in the APP gene causal of AD are situated at or near ␣, ␤, or ␥ secretase sites and alter APP proteolysis. 5 The precise normal function of APP is not known.
Presenilin 1 and 2 genes.
The PS1 gene on chromosome 14q24.3 was found in 1995 by Sherrington et al. 30 to contain five different missense mutations that cosegregated with early-onset familial AD. Since then, the PS1 gene has been associated with at least 60 different mutations in over 80 families causing early-onset AD between ages 35 and 65 years. [1] [2] [3] [4] All but two presenilin mutations are missense mutations. All except two mutations reside in regions that are conserved between PS1 and PS2 genes. The gene encodes a protein of 467 amino acid residues and is an integral membrane protein with 8 transmembrane domains. [1] [2] [3] [4] 30 Mutations in the PS1 gene account for a majority of autosomal dominant cases of AD. Mutation analyses indicate that the age at onset of AD in different PS1 families relates to the position and the type of amino acid substitution. [1] [2] [3] [4] The PS2 gene on chromosome 1q31-q42 has been identified in a group of families initially reported by Bird et al. 31 to be descended from a single German family that immigrated first to Russia and later to the United States. These Volga-German kindreds develop early-onset AD due to missense mutations in the PS2 gene. [32] [33] [34] It encodes for a protein of 448 amino acids and has overall homology with the PS1 protein amino acid sequence of 67%. [30] [31] [32] [33] [34] It is also an integral transmembrane protein. A missense mutation has been identified in Volga-German families, as have two additional missense mutations in an Italian and a Dutch family. 34 It is known that the presenilin genes are highly conserved throughout evolution. A high degree of homology of the human presenilin genes is present with sel-12, involved in the Notch cell-signaling pathway in C elegans for intercellular signaling during embryogenesis. 35 In PS1 transgenic mice and fibroblast cell cultures with the PS1 mutations, there is an increased syn-thesis of A␤ 42 . Fibroblasts in culture with PS1 mutations produce a 50% increase in 28 kD and 18 kD PS1 cleavage products. 36 The finding of a 50% increase in A␤ 42 production concurrent with a 50% increase in PS1 cleavage products suggests that presenilin cleavage has a direct effect on APP processing and A␤ synthesis. The presenilins may function to influence ␥-secretase activity or may in fact be ␥-secretase. ␤-And ␥-secretases are the postulated enzymes to cleave A␤ from its parent APP peptide. The finding that missense mutations in the presenilin genes increase A␤ synthesis and its own metabolic breakdown products by 50% in a parallel manner provides support for the view that the presenilin genes are important for the regulation of APP processing. The presenilins may be directing APP to specific intracellular endosomes containing ␥-secretase, producing preferentially A␤ 42 .
37,38 PS1 mutations increase caspase (cysteine-dependent aspartate specific proteases) activity, induce apoptosis, and downregulate the important signaling pathway of the unfolded protein response in the endoplasmic reticulum. 39 The increased levels of A␤ in PS1 mutant cells might therefore be the result of retention of the unfolded APP in the endoplasmic reticulum as a result of the impaired protein-folding system.
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Apolipoprotein E. APOE-⑀4 on chromosome 19q13.2 was demonstrated initially in late-onset AD families as well as sporadic late-onset individuals as being a risk factor for AD. [40] [41] [42] APOE-⑀4 heterozygous individuals had a threefold increased risk and homozygous persons an eightfold increased risk for developing AD by age 75 years compared to APOE-⑀3 heterozygous individuals. [40] [41] [42] APOE-⑀2 resulted in a later onset of disease and may be protective against developing AD. APOE-⑀4 is neither necessary nor sufficient to cause AD. Homozygous ⑀4/4 individuals may not develop AD and many ⑀3/3 individuals do. APOE is not a causal gene primarily but is a risk factor for developing AD as shown in large population studies. In families having APP mutations, with the exception of the 692 mutation, the APOE-⑀4 allele served as a risk factor as well, resulting in an earlier age at onset in this selected group of earlyonset AD individuals and families. No similar effect has been found in early-onset families having PS1 and PS2 gene mutations. [1] [2] [3] [4] The precise molecular cause of the increased risk for AD in APOE-⑀4 individuals may relate to the ⑀4 increased affinity for A␤ and its aggregation and subsequent formation of fibrils that become incorporated into the neuritic plaque. [43] [44] [45] Transgenic models. Transgenic mouse models of AD were introduced in 1995 by Games et al. 46 in which the mutant V717F human APP transgene was introduced into a mouse line. These transgenic mice progressively developed many of the pathologic features of the human condition, including numerous extracellular thioflavin S-positive A␤ deposits, neuritic plaques, limited synaptic loss, astrocytosis, and microgliosis. These features were in strong support of a primary role for increased A␤ synthesis from abnormally processed APP in the causation of this genetic form of AD-like pathology. 46, 47 This also supports the amyloid hypothesis for the sporadic form of human AD. This approach was extended in 1997 to demonstrate that development of amyloid-containing plaques in the V717F transgenic mouse was dependent on the expression of apolipoprotein E. Bales et al. 48 demonstrated that PDAPP ϩ/ϩ APOE Ϫ/Ϫ mice developed dramatically reduced levels of amyloidcontaining cortical and hippocampal plaques. The small number of A␤ deposits that were present had the characteristics of diffuse plaques and did not display thioflavine-S fluorescence. Holtzman et al., in 1999 49 and 2000, 50 extended these observations of the importance of APOE expression for A␤ deposition to occur in the V717F transgenic model. They found that human APOE-⑀3 and APOE-⑀4 suppressed early A␤ deposition at 9 months of age in the APP V717F ϩ/Ϫ transgenic mouse when compared with mice lacking APOE. However, by 15 months of age, expression of human APOE-⑀3 and -⑀4 in this mouse model expressing APP V717Fϩ/Ϫ and mouse APOE Ϫ/Ϫ resulted in significant fibrillar A␤ deposits with substantially (greater than a 10-fold) more fibrillar deposits in mice expressing human APOE-⑀4. They conclude that there is a critical concentration of APOE and A␤ that is required for mature, fibrillar A␤ to be deposited as plaque material. These data support the role of APOE as a pathologic chaperone facilitating either the formation or inhibiting the elimination of A␤ aggregates.
Lipoprotein receptor related protein (LRP).
LRP represents one of the receptors in the lowdensity lipoprotein receptor superfamily. [51] [52] [53] Eight key ligands (an eightfold way) potentially involved in AD interact with LRP, including cholesterol, APP, ␣2 macroglobulin (A2M), APOE, the cytosolic adaptor protein FE65, Mena (the mammalian homologue of enabled), Disabled-1 (Dab1), and Reelin, a large extracellular matrix protein. [51] [52] [53] A␤-APOE complexes binding to LRP may be an early event in the intracellular routing of APP and may affect the ratio with which APP is processed by ␣-secretase producing nonamyloidogenic fragments or the ␤/␥-secretases resulting in amyloidogenic A␤ fragments. A2M binds to A␤ as well as to LRP and may play a role with LRP in regulating extracellular A␤ levels. 54, 55 FE65 binds both to LRP and APP, forming a multiprotein complex that could regulate intracellular events central to AD. LRP contains the NPxY motif found in the cytoplasmic tails of many cell surface receptors, including the LDL superfamily receptors, and has been shown to be required for the clustering of the receptor in coated pits. Thus, the LRP receptor interacting with cholesterol, APP, A␤, A2M, and APOE may be involved in their internalization and subsequent trafficking to specific subcellular compart-ments. FE65, the peptide promoting APP and LRP binding, in turn has been shown to bind the protein mena, a protein that functions in cell migration. Further, an additional protein, DAB, binds both to APP and to LRP. Thus a model emerges involving a complex of proteins in close proximity involved in neuronal membrane signal transduction that may determine the fate of APP processing and A␤ synthesis. Hyman et al. 56 have postulated that LRP plays an important role in the clearance of APOE/A␤ and A2M/A␤ complexes. They emphasize a remarkable convergence of data relating AD pathology and LRP in support of this view, including: 1) senile plaques contain LRP; 2) LRP is the primary APOE receptor in neurons; 3) LRP can bind and clear APOE/A␤ complexes and A2M/A␤ complexes; and 4) the LRP gene on chromosome 12 may be a risk factor for AD. 56, 57 Kang et al. 57 have presented evidence in a subset of patients with the LRP C/C genotype having significantly more neuritic plaques than those with T-positive genotypes. Their data indicate that LRP may primarily affect neuritic plaque development. A meta-analysis by Beffert et al. found the LRP C allele remained over-represented in AD neuropathologically confirmed subjects (86.7%) when compared to control subjects (82.8%) (OR 1.34, 95% CI 1.16 to 1.54, p Ͻ 0.0001). 58 Wijsman et al. could find no evidence that LRP genotypes differ in age at onset for AD. 59 The LRP gene is located on chromosome 12 and the evidence cited that it has only a weak correlation with AD has suggested that another locus on chromosome 12 is a more likely candidate as a risk factor. Several studies have identified a chromosome 12 association with AD. However, it has not been identified with certainty. [60] [61] [62] A locus near the gene for A2M, a LRP ligand, is a possible candidate. 62 Cholesterol also binds to LRP and cholesterol metabolism has not yet been fully explored for its role in AD pathology. APOE transports cholesterol through the brain and APOE ⑀4 may produce its increased risk in part through abnormal cholesterol metabolism. In this regard, Simons et al. showed that reducing the cellular cholesterol level of hippocampal neurons in vitro by 70% with lovastatin and methyl-␤-cyclodextrin caused A␤ production to be completely inhibited while the generation of APP was unperturbed. The inhibition of A␤ formation was fully reversible by the readdition of cholesterol to previously depleted cells. 63, 64 Thus, cholesterol is required for A␤ formation, implying a linkage between cholesterol, A␤, and AD. More specifically, these data suggest that ␤-and ␥-secretase activities are affected by cholesterol depletion and that cholesterol reducing agents have the potential to be involved in the prevention and treatment of AD. Although the role of LRP in AD is not firmly established, additional research is warranted to define its potential role in integrating the various molecules into which it comes into contact.
Tau gene. The neurofibrillary tangles present intraneuronally in AD are composed predominately of hyperphosphorylated tau. Tau binds normally to microtubular protein, which forms the cytoskeleton of axons and stabilizes them. Tau that is removed from its microtubular binding domains autopolymerizes and is phosphorylated, preventing it from rebinding to microtubules. Polymerized-hyperphosphorylated tau forms the paired helical filaments (PHF) or neurofibrillary tangles of AD. The precise molecular basis for their formation is not clear. Wilhelmsen et al. 65 have shown that specific mutations in the tau gene on chromosome 17q21-22 are causal of frontotemporal dementia and parkinsonism (FTDP-17). It is hoped this information will provide critical data to better appreciate tangle production in AD. No tau gene exon 2, 3, or 10 missense nor exon 10 splice site mutations seen in some families described with autosomal dominant FTDP-17 by Goedert et al., 66, 67 Poorkaj et al., 68 Hutton et al., 69 and Hong et al. 70 have been found in any AD patient's brain. The molecular characterization of tau mutations will be critical to deciphering the molecular pathology of tau polymerization into PHF in AD.
Amyloid biomarkers. Several new amyloid biomarkers are being developed as possible diagnostic blood tests for AD. Biomarkers for AD include elevated plasma levels of A␤ 42 in individuals over 65 years of age. Individuals studied in this manner with elevated A␤ plasma levels over age 65 had a higher risk for developing AD compared to those with normal values. 71, 72 The elevated plasma A␤ 42 levels fell to lower values as patients developed clinical symptoms of AD. CSF levels of A␤ 42 also tend to fall with disease progression. The fall in CSF A␤ 42 levels has been correlated with a rise in CSF tau, related to increased neurofibrillary turnover and clearance in the CSF. 5 The mean ratio of the 120 -130 kD APP isoform to the 110 kD APP isoform in blood platelets in patients with AD has been shown to be significantly lower than that of control subjects. 73, 74 APP processing by platelets in patients with AD is different from that of control subjects. Altered APP platelet processing relates to an analogous alteration in APP processing occurring in brain areas affected by AD and this approach shows promise in becoming a useful diagnostic test.
Protective genes. Protective genes may prevent AD. Natural selection against AD must have some survival value. As the genetic degree of Cherokee Indian ancestry increased in a cohort of patients studied in Oklahoma, the representation of AD decreased. 75 Selection of Native American tribal chiefs until only recently was usually by matrilineal inheritance from mother to son. Selection of a protective gene against AD would invoke enhanced survival of the cohort under the chief 's control and promote perpetuation of his descendants' DNA, analogous to the selective advantage of a gene during childbearing years having survival value. The low percentages of AD in high genetic Cherokee Indians were not changed by the APOE ⑀4 allele. These data are intriguing as they indicate that the Cherokee Indians with varying genetic dilution are at risk differentially for AD, and they imply that complex protective and disease-causal genetic factors may be involved in a variable manner for the European, Asian, and Native American populations. In view of the origin of American Indian tribes from southeastern Asia, a lower prevalence rate for AD in the Chinese of Hong Kong compared with white populations is noteworthy. 76 The finding of a possible genetic protective effect against developing AD by having a high genetic degree of Cherokee Indian ancestry is in accord with this concept. Similar data have been reported by Hendrie et al., who have reported that AD is rare in the Cree Indian tribe as compared with an urban white population. 77 Pericak-Vance et al. 78 have reported a low prevalence of AD in another outbred population, the Amish of Indiana, and concluded that this finding is only partially explained by their decreased frequency of the APOE ⑀4 allele. 78 The putative AD protective gene might have provided relative resistance against smallpox, to which Native American populations were highly vulnerable in the past. Smallpox pandemics may have provided a "bottle-neck" phenomenon, with survivors having been selected for relative resistance against smallpox. Relative resistance against smallpox may have been provided by the putative AD protective gene, and thus present-day Native American Indians may have acquired resistance coordinately against smallpox and AD.
Molecular linkages (figure).
It is important to review established molecular linkages in AD pathogenesis and speculate on possible new ones. APP processing produces A␤ 40 and A␤ 42 , which polymerizes to form (A␤ 40 ϩ 42 ) n as ␤-pleated sheet plaques. The microtubule-stabilizing protein tau is hyperphosphorylated to form neurofibrillary tangles. APOE-⑀4 promotes increased plaque and tangle formation in the AD brain and in sporadic AD, degradation and clearance of (A␤ 42 ) n is impaired. How these various molecular events interrelate is not clear but a new mouse model is providing insight. In this regard, Hiesberger et al., 79 including Joachim Herz and Marc Mumby, members of our AD Center, have studied a double knockout strain of mice, lacking two members of the low-density lipoprotein (LDL) receptor gene family, the cell surface proteins very lowdensity lipoprotein receptor (VLDLR) and APOE-R2. In this double knockout strain, there is an increased amount of the hyperphosphorylated microtubulestabilizing protein tau. Linking VLDLR/APOE-R2 expression to (tau-PO 4 ) n is of considerable interest as now amyloidogenesis and neurofibrillary tangle generation may have expression in part due to dysregulation of VLDLR and APOE-R2. This finding suggests that tau hyperphosphorylation is regulated directly, in part, or indirectly by the APOE-R2/VLDLR signaling pathway and that the tau hyperphosphorylation state contributes to the disruption of microtubules. 79 A subtle alteration of cellular signals initiated by members of the LDL receptor gene superfamily might affect the stability of the neuronal cytoskeleton and promote neuronal cell death. Hiesberger et al. 79 have shown that both VLDLR and APOE-R2 can bind Reelin on their extracellular domains. Inside the cell, the Reelin signal is received by the cytosolic adapter protein Dab1, which contains a protein interaction domain that binds to the cytoplasmic tail of the VLDLR. Reelin stimulates tyrosine phosphorylation of Dab1 and subsequently Dab1 protein levels are downregulated by a yet unknown process. 79 A signal pathway induced by Reelin acting on VLDLR and APOE-R2 receptors modulates levels of cytoplasmic Dab1 tyrosine phosphorylation and also tau phosphorylation. Similarly, the mouse mutant reeler, lacking Reelin, also exhibits increased tau phosphorylation. 79 Exactly how the cell surface VLDLR/APOE-R2 signal is transmitted is not known. 79 The observations of Hiesberger et al. 79 clearly suggest that tau hyperphosphorylation is regulated by the Reelin-VLDLR-APOE-R2-Dab1 signaling pathway and that this pathway may be altered and may contribute to tau hyperphosphorylation and neuronal tangle formation in AD. 79 Additional data by Patrick et al. 80 has demonstrated that cyclin-dependent kinase 5 (Cdk5), which is partially responsible for the hyperphosphorylation of tau, has increased activity in AD brain. They found that for Cdk5 to be activated it has to associate with its plasma membrane regulatory subunit, p35. A truncated form of p35, p25, also accumulated in neurons in AD brain and this accumulation correlated with an increase in Cdk5 kinase activity. 80 In vivo, the p25/Cdk5 complex hyperphosphorylates tau, which reduces tau's ability to associate with microtubules. 80 The plasma membrane location of p35 also supports a possible linkage of altered tau phosphorylation with the Reelin data.
As mentioned previously, 48 APOE knockout PDAPP mice having the human APP717 codon mutation produced minimal amyloid-containing plaque compared to wild-type mice. If APOE-R2 receptors deficient in being activated by their ligand APOE in these APOE knockouts produce almost no plaque, then it is possible to suggest on theoretical grounds that dysregulated cell surface APOE-R2 receptors might alter amyloidogenesis, resulting in excessive amyloid plaque formation. APOE-⑀4, which is an AD risk factor and binds to APOE-R2, may facilitate the altered membrane signal transduction. Polymorphism and quantification studies of APOE-R2, the VLDL receptor, and the cytosolic adaptor protein Dab1 should be undertaken. Levels of tyrosine phosphorylated Dab1 should be measured in AD brain as an index of the efficiency and activity of this transmembrane signaling pathway. Altered signaling via this transduction pathway may direct transported A␤ internalized via the LRP or released from the endoplasmic reticulum into the incorrect subset of early endosomes. Misdirected A␤ into the wrong endosomal circuit may be in part responsible for it being released extracellularly and included into plaques. Thus, this cell surface membrane receptor model of AD provides a potential linkage for the coordinate expression of amyloid plaques and tau hyperphosphorylated tangles by variable alteration of signal transduction from cell surface APOE-R2 and VLDL and LRP receptors to cytosolic targets including Dab1 and subsequent activation of nonreceptor tyrosine kinases and their substrates. The downstream targets of this hypothetical kinase cascade initiated by Dab1 are currently unknown but may be directly concerned with A␤ trafficking.
Tomiyama et al. provide evidence for APOE cell surface membrane receptor-mediated endocytosis of APOE/A␤ complexes. 81 Lysosomal APOE/A␤ aggregates are postulated to accumulate, causing altered APP metabolism and subsequent neuronal degeneration. With neuronal death, intracellular A␤ contributes to some degree, it is hypothesized, to the extracellular deposits. 81 The VLDL receptor has also been reported to be genetically associated with sporadic AD in the Japanese 82 but not in Caucasians. 83 Tanzi has raised the more general issue of possible common population polymorphisms (CPP) distributed throughout the genome as risk factors for AD. 84 He includes LRP, A2M, APOE, and FE65, among others, as potential important risk factors that are additive and will trigger the pathogenesis of AD in association with environmental risk factors. 84 Van Uden et al. 85 more directly state that LRP may be central to AD pathogenesis as all proteins genetically associated with AD are linked via a single pathway to the LRP. Specifically, they found that transgenic mice overexpressing the M146L or L286V PS1 mutation show decreased levels of LRP expression in neuronal populations where PS1 and LRP are closely colocalized or coexpressed. 85 They point out that if LRP is downregulated, internalization of A2M/A␤ complexes may be decreased, resulting in increased serum A␤ levels, as observed in PS1 transgenic mice and PS1 patients. 85 One can imagine, for the first time, molecular linkages involving cell surface membrane receptors (LRP, APOE, and VLDLR, among others), as suggested here, for a central unified hypothesis of AD pathogenesis, altering both amyloidogenesis and tau hyperphosphorylation. A standard model for AD pathogenesis can now be stated with the major hypotheses and also including altered cell surface membrane receptor signaling as a unified concept for the abnormal processing of APP, A␤ transport, and tau hyperphosphorylation (table).
Molecular therapy.
Of great interest are two recent observations that are directed specifically at altering the pathology of the disease and offer the potential of patient therapy. Schenk et al. 86 have reported that mice carrying the human V717F transgene overexpress the mutant APP and progressively develop the neuropathologic features of AD in an age-and brain region-dependent manner. Immunization with A␤ 42 prevented the development of ␤-amyloid plaque formation, neuritic dystrophy, and astrogliosis. This prevention of plaque formation was demonstrated before the onset of AD type neuropathologies at 6 weeks of age and even in older animals at 11 months of age. It remains to be determined if reduction of amyloid-containing extracellular plaques in this experimental paradigm also reverses the development of a behavioral deficit. Fulfillment of the amyloid hypothesis requires that prevention of the amyloid burden results in clinical improvement. 87 Of great interest are the reports of Vassar et al., 88 Yan et al., 89 and Sinha et al. 90 in 1999 of the cloning, isolation, and characterization of the membranebound aspartyl protease (Asp2) that cleaves fulllength APP at the ␤-secretase cleavage site and was found to be the predominant ␤-cleavage activity in human brain. Overexpression of the ␤-secretase gene increased the amount of ␤-secretase cleavage products and these were cleaved exactly and only at known ␤-secretase positions. Demonstration of the specific ␤ site APP-cleaving enzyme (BACE) provides a direct approach to develop pharmacologic agents that can specifically inhibit this gene's expression and/or its identified protease. ␥-Secretase inhibition by a specific inhibitor is also a potential target to inhibit A␤ synthesis. In this regard, Wolfe et al. postulate with compelling data that PS1 is either a unique cofactor for ␥-secretase or is itself ␥-secretase. 91 Kimberly et al. 92 have shown that both PS1 and PS2 have ␥-secretase activities and that transmembrane aspartates in PS1 and PS2 are obligatory for ␥-secretase activity and A␤ generation. Inhibition of ␤-or ␥-secretase would prevent A␤ synthesis and affect the rate of plaque production.
Prevention of formation of hyperphosphorylated tau by inhibition of the putative protease that cleaves p35, a regulatory subunit of cyclin-dependent kinase 5 (Cdk5), to its active form, p25, or by direct inhibition of Cdk5 kinase activity, which is increased in AD brain, are approachable goals. 80 Increased tau kinase activity and decreased tau phosphatase activity have been shown to be the direct cause of hyperphosphorylated tau. What the molecular regulatory events are to shift the balance between kinase and phosphatase activities leading to hyperphosphorylation of tau and paired helical filament tau remain unresolved. 80 A five-residue peptide that inhibits A␤ fibrillogenesis, disassembles preformed fibrils in vitro, and prevents neuronal death induced by fibrils in cell culture has been described by Soto et al. 93 This ␤-sheet breaker peptide also significantly reduced A␤ deposition in vivo and blocked the formation of amyloid fibrils in a rat brain model of amyloidosis. It is a novel approach and theoretically offers a unique approach to prevent amyloid plaque formation in AD.
McLean et al. 94 have found a threefold increase of soluble A␤ in AD brain, which correlated with markers of disease severity. There was a higher proportion of A␤ 42 in the soluble fractions, possibly representing an intracellular and more neurotoxic pool. They point out that if the difference between normal and disease state is only a mean threefold elevation of soluble A␤, then reduction of this steadystate level to control levels may be a goal for therapy. 94 This observation correlates with therapeutic approaches attempting to inhibit A␤ synthesis by inhibiting ␤-/␥-secretase activities.
Nakagawa et al. 95 have identified a specific cysteine-dependent aspartate-specific protease, caspase 12, which is localized to the endoplasmic reticulum of the cell and participates in the genetic program of cell death induced by A␤. Their results offer another potential target for protease inhibitor therapy to be developed.
In a population-based study of elderly African Americans, increasing total cholesterol (TC) increased AD risk in a group with no ⑀4 alleles. These 3. In the autosomal dominant forms of early onset AD with mutations in the APP, PS1, or PS2 genes, there is increased production of A␤ 40 and/or 42 in patient plasma or patient fibroblasts in culture.
4. Aged patients with Down syndrome have increased A␤ synthesis, formation of typical AD plaques and tangles, and may develop a dementia of AD type.
5. Sporadic AD, the majority of patients, appear to have a decreased clearance of A␤ from brain and CSF resulting in accumulation in brain as plaques and also as intracellular A␤ and not increased A␤ synthesis as in the genetic forms of disease.
6. A␤ deposition in brain is a very early and toxic event in AD neuropathology and precedes clinical symptoms of AD, suggesting it is the prime pathogenic cause of AD. It is a central feature of the amyloid hypothesis of AD pathogenesis.
7. Activation of ␤-and ␥-secretases is necessary to cleave A␤ from APP and inhibition of either of these two enzymes would prevent A␤ synthesis and theoretically prevent A␤ from aggregating into plaques. Protease inhibitors have a real role to play in preventing AD.
8. Prevention of amyloid plaque formation or intracellular A␤/ APP amyloidogenic fragments has not yet been shown to correlate with behavioral improvement in transgenic mouse models of AD. Proof of the amyloid hypothesis of the causation of AD will require such a relationship initially in experimental animal models and ultimately in patients.
9. APOE-⑀4 is a risk factor for developing AD. It acts as a pathologic chaperone either aiding in the polymerization of A␤ into ␤-pleated sheets of amyloid in plaques or by retarding the clearance of A␤.
10. Cell surface membrane receptor signaling involving APOE-R2, VLDLR, LRP, and their ligands, including APOE, A␤, APP, ␣2 macroglobulin, and Reelin, may be directly involved in AD pathogenesis due to altered signaling pathways misdirecting APP processing and/or A␤ degradation and clearance and the degree of tau hyperphosphorylation. Genetic polymorphisms in these receptors and in single nucleotide polymorphisms in the patient's genome are molecular factors that are linked to cause AD.
results suggest that TC may be a potentially modifiable environmental risk factor for AD and thus statin (HMG Co-A reductase inhibitor) therapy to reduce serum TC might be of value in these patients. 96 Translation of these data related to specific genetic mutations causal of AD and associated risk factors including APOE and LRP must now be undertaken to provide insight into the cause of nongenetic, sporadic AD. The objectives and challenge are a clearer understanding of increased A␤ aggregation, and decreased degradation and clearance of A␤, which are early events in sporadic AD. The risk of A2M and AD remains unresolved, with data recently presented supporting a significant association between the A2M gene on chromosome 12 and a weak association. 97, 98 It remains of considerable importance that many of the described genetic polymorphisms that have been associated with AD are related to the LRP or LRP ligands including A2M. 97 The issue of clearance of A␤ by forming A2M complexes via an LRP-dependent mechanism and alteration of this process due to A2M polymorphisms remains a vital matter to resolve. 97, 98 Research strategies need to be pursued comprehensively in patients to inhibit plaque formation with A␤ 42 active immunization or by passive immunization with monoclonal antibodies to A␤. Inhibition of ␤-and ␥-secretases by pharmacologic agents to reduce amyloidogenesis in patients is a major and realistic goal. In this regard, Nä slund et al. have shown that the levels of five neocortical areas of brain for both A␤ 42 and A␤ 40 were elevated and correlated with the degree of cognitive decline. 99 The frontal cortex level of A␤ was elevated before the occurrence of significant tau pathology. These findings are important as they show A␤ burden rather than plaque count is a more sensitive and reliable correlation with the degree of cognitive loss and dementia and emphasize the therapeutic rationale for inhibiting APP processing with ␤-/␥-secretase inhibitors early in the disease process. Panegyres et al. 100 did not find a differential expression of APP mRNA isoforms in AD, which supports the hypothesis that post-translational events in APP metabolism are important in amyloidogenesis and the pathogenesis of AD. Thus, therapies that promote A␤ degradation and clearance from brain need to be emphasized in nongenetic, sporadic AD rather than research directed at differential gene expression.
Interleukin-1 (IL-1) polymorphisms in the IL-1A and IL-1B genes have been recently reported to be strongly associated with early-onset AD.
101,102 IL-1 is a proinflammatory cytokine that is overexpressed in microglia in AD brain. These newly found ADassociated polymorphisms are additional common population polymorphisms that are probably operating as susceptibility factors. 103 Anti-inflammatory therapies that modulate IL-1-mediated inflammation may be highly useful in treating and preventing AD. Testing patients with cognitive impairments or dementia for these high-risk IL-1 polymorphisms may be a means, as emphasized by Tanzi, to develop genotype-specific guided treatments. 103 Reducing the mean age at onset of AD by 5 years will reduce the prevalence of disease by at least onethird. The end of the beginning of research to achieve these molecular therapies has occurred. The beginning of the end of AD based on current momentum and the crescendo of these recent achievements will soon follow.
